Government
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
Genentech, a Roche company, announced the U.S. Food and Drug Administration (FDA) had approved its Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in adults and children two months of age and older.
In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order on Thursday that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.
The FDA set a PDUFA target date of March 7, 2021 for aducanumab, Biogen said.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.
According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.
The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.
PRESS RELEASES